PART I . Unless the context otherwise requires, the terms Janux Therapeutics, Janux, we, us, our and similar references in this Annual Report on Form 10-K refer to Janux Therapeutics, Inc. Overview We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. ...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076918 | EDGAR | 103K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029177 | EDGAR | — |
| 2024-03-08 | 2023-12-31 | 0000950170-24-028659 | EDGAR | — |
| 2023-03-10 | 2022-12-31 | 0000950170-23-007311 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0000950170-22-004171 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269799 | EDGAR | 67K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105069 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067083 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122370 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092857 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-054966 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060288 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039898 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019689 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024511 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016082 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008984 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001193125-26-076627 | EDGAR | 2K words |
| 2026-01-22 | 0001193125-26-019520 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269518 | EDGAR | — |
| 2025-09-19 | 0001193125-25-209259 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105010 | EDGAR | — |
| 2025-06-13 | 0000950170-25-086284 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066969 | EDGAR | — |
| 2025-02-27 | 0000950170-25-029165 | EDGAR | — |
| 2024-12-05 | 0001193125-24-271578 | EDGAR | — |
| 2024-12-02 | 0000950170-24-132302 | EDGAR | — |
76 total filings indexed. 49 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001817713 |
| Ticker | JANX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.januxrx.com |
| Listed | 2021-06-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report